Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson’s Disease
Objective: This study aims to identify pre-treatment indicators for Parkinson’s disease (PD) patients who respond well to monoamine oxidase type B inhibitors (MAOBIs). Background: MAOBIs,…Opicapone for OFF Motor Fluctuations in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials
Objective: To evaluate the efficacy of opicapone 50 mg in reducing OFF time and improving motor function in Parkinson’s disease (PD) patients with motor fluctuations.…Antiparkinson Medication Reduces the Probability of the Multiple Step Saccade Pattern During a Memory-Guided Saccade Task
Objective: We wanted to determine how the multiple step saccade pattern responds to antiparkinson medication, as it has been proposed to use this pattern as…Assessment of the impact of the diabetic features hyperglycemia and insulin resistance on fibril induced synucleinopathy
Objective: Investigate the effects of diabetic features on the induction and severity of synucleinopathies such as Parkinson’s disease (PD). Background: Type 2 diabetes (T2D) is…Tavapadon Is Not Associated With Increased Daytime Sleepiness in People With Parkinson’s Disease
Objective: To evaluate daytime sleepiness in people with Parkinson’s disease (PD) treated with tavapadon as monotherapy (TEMPO-1; NCT04201093) or adjunctive to levodopa (TEMPO-3; NCT04542499). Background:…Safety Profile of Opicapone in Elderly and Very Elderly Population
Objective: This study aimed to characterize the safety profile of opicapone (OPC) in the elderly and compare post-marketing safety between (A) very elderly patients (≥…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…European Experience with Long-term Continuous Subcutaneous Apomorphine Infusions at Higher Doses
Objective: Outline European Union (EU) long-term experience with higher doses (≥6 mg/h or ≥100 mg/d) of continuous subcutaneous apomorphine infusion (CSAI). Background: The EU TOLEDO…The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease
Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…A Phase II Randomized, Parallel, Double-blind, Placebo-controlled Study of the Efficacy and Safety of WD-1603 in Subjects with Parkinson’s Disease
Objective: To investigate the effectiveness, safety and pharmacokinetics of WD-1603 carbidopa-levodopa controlled-release tablets in subjects with Parkinson's disease. Background: The development of drug products that…
- « Previous Page
- 1
- …
- 299
- 300
- 301
- 302
- 303
- …
- 1942
- Next Page »